ArticleFrontiers in clinical diabetes and healthcare2025
Impact of the COVID-19 pandemic on the Andalusian program for early detection of diabetic retinopathy: a population-based study.
Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To analyze the impact of the COVID-19 pandemic on the activity and outcomes of the Andalusian Program for Early Detection of Diabetic Retinopathy (APDR). Methods: A retrospective observational study was conducted during 2018-2023. The following variables were analyzed annually: newly included patients, retinal photographs performed, and pathological findings categorized by severity. Moderate-to-severe non-proliferative and proliferative retinopathy were classified as vision-threatening diabetic retinopathy (VTDR). Results: In 2020 and 2021, the number of newly included patients (11,897 and 18,343, respectively) and retinal photographs performed (39,667 and 64,092, respectively) decreased compared to previous years (2018 and 2019: 25,940 and 30,807 new patients, respectively; 85,171 and 100,849 retinal photographs, respectively). In 2022, activity levels increased 160% compared to 2019. The proportion of VTDR cases remained stable at 0.163%, 0.14%, and 0.075% during 2021, 2022, and 2023, respectively, compared to the prepandemic period (0.168% and 0.117% in 2018 and 2019, respectively). Conclusions: Despite the slowdown in activity during the COVID-19 pandemic, the post-pandemic proportion of VTDR cases diagnosed through the APDR remained stable, suggesting resilience against severe outcomes despite healthcare disruption. The program has demonstrated an effective recovery. Ongoing long-term monitoring is essential to fully assess the pandemic's potential impact on late-stage complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.